The Patent Finder
AT

Aclaris Therapeutics, Inc.

First filing 2002
OverviewNotableFeesChangesFamiliesPatent listSources & methods

18 patents currently held

7 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Aug 2033. from the record

Of the 7 now held by other companies, 4 name Mayne Pharma LLC as their current owner, and 3 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Aug 2033
Next term end
11
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents fee due within 90 days all others Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Substituted Pyrrolopyridine Jak Inhibitors and Methods of Making and Using the Same US 10,981,906
Cited by 10 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2038.
Ends Nov 2038 · High confidence
Also notable
Heterocyclic Itk Inhibitors for Treating Inflammation and Cancer US 10,150,783
Granted 2018. Computed term ends 2036.
Ends Jan 2036 · High confidence
Also notable
Pyrrolopyrimidine Itk Inhibitors US 11,021,482
Granted 2021. Computed term ends 2039.
Ends Aug 2039 · High confidence

Formerly held, still cited

Notable
The most cited patent in this portfolio, cited by 119 later US patents, top 5% of utility patents granted in 2014 in our data. Protection runs to 2031.
now held by Epi Health, LLC
Ends Dec 2031 · High confidence
Also notable
Cited by 19 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
now held by Mayne Pharma LLC
Ends Jun 2035 · Medium confidence
Also notable
Cited by 43 later US patents, top 25% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
now held by Epi Health, LLC
Ends Oct 2029 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Dec 11 to 16, 2026 · next Dec 11
  • 2 fees due Feb 25 to 28, 2027 · next Feb 25
  • 2 fees due Mar 26 to 29, 2027 · next Mar 26
  • 1 fee due May 21, 2027
    The maintenance fee for Pyrrolopyrimidine Itk Inhibitors (US 11,820,775) comes due May 21, 2027. Unpaid by Nov 22, 2027, it lapses early.
  • 1 fee due Jun 19, 2027
    The maintenance fee for Oral Compositions of MK2 Pathway Inhibitor for Treatment of Immune Conditions (US 11,844,801) comes due Jun 19, 2027. Unpaid by Dec 20, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 9,056,110Substituted Pyrimidinone-Phenyl-Pyrimidinyl Compounds
In force
 · High confidence
In forceHigh confidence
US 9,115,089Methyl/Fluoro-Pyridinyl-Methoxy Substituted Pyridinone-Pyridinyl Compounds and Fluoro-Pyrimidinyl-Methoxy Substituted Pyridinone-Pyridinyl Compounds
In force
 · High confidence
In forceHigh confidence
US 9,636,333Methyl/Fluoro-Pyridinyl-Methoxy Substituted Pyridinone-Pyridinyl Compounds and Fluoro-Pyrimidinyl-Methoxy Substituted Pyridinone-Pyridinyl Compounds
In force
 · High confidence
In forceHigh confidence
US 9,145,393Arylpyridinone Itk Inhibitors for Treating Inflammation and Cancer
In force
 · High confidence
In forceHigh confidence
US 10,150,783Heterocyclic Itk Inhibitors for Treating Inflammation and Cancer
In force
 · High confidence
In forceHigh confidence
US 10,316,038Pyrrolopyrimidine Itk Inhibitors for Treating Inflammation and Cancer
In force
 · High confidence
In forceHigh confidence
US 10,981,906Substituted Pyrrolopyridine Jak Inhibitors and Methods of Making and Using the Same
In force
 · High confidence
In forceHigh confidence
US 11,739,086Substituted Pyrrolopyridine Jak Inhibitors and Methods of Making and Using the Same
In force
 · High confidence
In forceHigh confidence
US 12,281,111Substituted Pyrrolopyridine Jak Inhibitors and Methods of Making and Using the Same
In force
 · High confidence
In forceHigh confidence
US 11,021,482Pyrrolopyrimidine Itk Inhibitors
In force
 · High confidence
In forceHigh confidence
10 of 18 patents shown.
Pro members see all 18.
Pro members: see all 18 patents
Also on record, not counted in the 18: 7 patents in force now held by others · 19 patents ended · 10 applications pending · 16 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited